Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist

Affiliations

¹ Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jeferguson@mdanderson.org.
² Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.

Comment

James E Ferguson 3rd et al. Eur Urol. 2017 Jun.

. 2017 Jun;71(6):987.

doi: 10.1016/j.eururo.2017.02.015. Epub 2017 Feb 23.

¹ Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jeferguson@mdanderson.org.
² Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Comment on

Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J. Chen W, et al. Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5. Nature. 2016. PMID: 27595394 Free PMC article.